Can-Fite BioPharma Ltd. (NYSE:CANF) has a beta value of 1.09 and has seen 2,154,894 shares traded in the recent trading session. The company, currently valued at $27.29 Million, closed the recent trade at $2.0601 per share which meant it lost -$0.1 on the day or -5.42% during that session. The CANF stock price is -140.28% off its 52-week high price of $4.95 and 47.58% above the 52-week low of $1.08. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.7 Million shares traded. The 3-month trading volume is 1.12 Million shares.

The consensus among analysts is that Can-Fite BioPharma Ltd. (CANF) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 2 have rated it as a Hold, with 2 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.3.

Can-Fite BioPharma Ltd. (NYSE:CANF) trade information

Despite being -8.45% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Jun 29 when the CANF stock price touched $2.45-1 or saw a rise of 17.11%. Year-to-date, Can-Fite BioPharma Ltd. shares have moved -38.46%, while the 5-day performance has seen it change 14.1%. Over the past 30 days, the shares of Can-Fite BioPharma Ltd. (NYSE:CANF) have changed -5.54%. Short interest in the company has seen 166.49 Million shares shorted with days to cover at 148.65.

Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 191.25% from current levels. The projected low price target is $5 while the price target rests at a high of $7. In that case, then, we find that the current price level is +239.79% off the targeted high while a plunge would see the stock lose 142.71% from current levels.

Can-Fite BioPharma Ltd. (CANF) estimates and forecasts

Figures show that Can-Fite BioPharma Ltd. shares have underperformed across the wider relevant industry. The company’s shares have lost -36.52% over the past 6 months, with this year growth rate of -61.52%, compared to 11% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 76.4% and 64.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be -45.9%.

2 analysts offering their estimates for the company have set an average revenue estimate of $250Million for the current quarter. 2 have an estimated revenue figure of $250Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $389Million and $1.15 Million respectively for this quarter and the next, and analysts expect sales will grow by -35.7% for the current quarter and -78.3% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +0% over the past 5 years. Earnings growth for 2020 is a modest +56.1% while over the next 5 years, the company’s earnings are expected to increase by 0%.